Begin main content

Levodopa / carbidopa (Drug Plan Submission)

Last Updated: October 24, 2018
Result type: Reports
Project Number: SR0557-000
Product Line: Common Drug Review

Generic Name: Levodopa / carbidopa (Drug Plan Submission)

Brand Name: Duodopa

Manufacturer: AbbVie Corporation

Indications: Parkinson's disease

Manufacturer Requested Reimbursement Criteria1: Not applicable. Drug plan submission.

Submission Type: Resubmission

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: August 22, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedJanuary 11, 2018
Patient group input closedMarch 02, 2018
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsMarch 14, 2018
Patient group comments on input summary closedMarch 21, 2018
Clarification:

- Patient input summary feedback received

Submission receivedFebruary 08, 2018
Submission accepted for reviewFebruary 23, 2018
Review initiatedFebruary 26, 2018
Draft CDR review report(s) sent to applicantMay 10, 2018
Comments from applicant on draft CDR review report(s) receivedMay 22, 2018
Redaction requests from applicant on draft CDR review report(s) receivedMay 29, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantJuly 06, 2018
Canadian Drug Expert Committee (CDEC) meetingJuly 18, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJuly 31, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedAugust 15, 2018
CDEC Final Recommendation issued to applicant and drug plansAugust 22, 2018
CDEC Final Recommendation postedAugust 24, 2018
Final CDR review report(s) and patient input postedSeptember 18, 2018

Tags

nervous system, carbidopa, gels, infusions, parenteral, levodopa, parkinson disease, parkinson, Duodopa; duopa; Parkinson disease